Literature DB >> 17186532

Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung.

Shin Myung Kang1, Hyun Ju Kang, Ju Hye Shin, Hoguen Kim, Dong Hwan Shin, Se Kyu Kim, Joo-Hang Kim, Kyung Young Chung, Sung Kyu Kim, Joon Chang.   

Abstract

BACKGROUND: Adenosquamous carcinoma of the lung is composed of adenocarcinomatous and squamous cell carcinomatous components. The epidermal growth factor receptor (EGFR) mutations occur mostly in adenocarcinomas and rarely in squamous cell carcinoma of lung. Attempts to investigate the EGFR mutation status in each component of adenosquamous carcinoma and to characterize the patients according to mutation status may help to understand the histogenesis of adenosquamous carcinoma.
METHODS: The mutation status of EGFR kinase domain from exon 18 to 21 was investigated in 25 Korean patients with adenosquamous carcinoma by polymerase chain reaction-single strand conformation polymorphism using the tissues of each component from the adenosquamous carcinoma tumor. Clinicopathologic characteristics of the patients according to the status of EGFR mutations were compared.
RESULTS: EGFR mutations were identified in 11 (44%) patients: 9 mutations were in exon 19, 1 in exon 20, and 1 in exon 21. EGFR mutations were significantly more frequent (P = .005) in women (n = 8, 80%) than men (n = 3, 20%). Never-smokers (n = 8, 62%) had EGFR mutations more commonly than smokers (n = 3, 25%; P = .111). Identical EGFR mutations in both components of adenosquamous carcinoma were confirmed by nucleotide sequencing.
CONCLUSIONS: The frequency of EGFR mutation and clinicopathologic characteristics of the EGFR mutants in adenosquamous carcinoma are similar to those of Asian patients with adenocarcinomas. Identical EGFR mutations in both components suggest the possibility of monoclonality in the histogenesis of adenosquamous carcinoma. (c) 2007 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17186532     DOI: 10.1002/cncr.22413

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  44 in total

1.  Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma.

Authors:  Zhaohui Jin; Marie Holubek; William R Sukov; Christopher A Sattler; Anne E Wiktor; Robert B Jenkins; Tsung-Teh Wu; Harry H Yoon
Journal:  Am J Clin Oncol       Date:  2019-02       Impact factor: 2.339

2.  Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.

Authors:  Bibhu Ranjan Das; Sangeet Bhaumik; Firoz Ahmad; Aziz Mandsaurwala; Heena Satam
Journal:  Pathol Oncol Res       Date:  2015-01-31       Impact factor: 3.201

3.  Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer.

Authors:  Young Joo Lee; Hyo Sub Shim; Young Ae Kang; Su Jung Hong; Hyun Ki Kim; Hoguen Kim; Se Kyu Kim; Sung Ho Choi; Joo-Hang Kim; Byoung Chul Cho
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-17       Impact factor: 4.553

4.  Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.

Authors:  Paul K Paik; Anna M Varghese; Camelia S Sima; Andre L Moreira; Marc Ladanyi; Mark G Kris; Natasha Rekhtman
Journal:  Mol Cancer Ther       Date:  2012-08-14       Impact factor: 6.261

Review 5.  Role of genotyping in non-small cell lung cancer treatment: current status.

Authors:  Laura Bonanno; Adolfo Favaretto; Massimo Rugge; Miquel Taron; Rafael Rosell
Journal:  Drugs       Date:  2011-12-03       Impact factor: 9.546

Review 6.  Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.

Authors:  Yi Shao; Dian-Sheng Zhong
Journal:  Int J Clin Oncol       Date:  2017-11-07       Impact factor: 3.402

7.  Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.

Authors:  Marie Brevet; Maria Arcila; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2010-01-21       Impact factor: 5.568

8.  Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.

Authors:  Maureen F Zakowski; Sanaa Hussain; William Pao; Marc Ladanyi; Michelle S Ginsberg; Robert Heelan; Vincent A Miller; Valerie W Rusch; Mark G Kris
Journal:  Arch Pathol Lab Med       Date:  2009-03       Impact factor: 5.534

9.  Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China.

Authors:  Jianlin Xu; Yanwei Zhang; Bo Jin; Tianqing Chu; Xue Dong; Haitang Yang; Dan Wu; Yuqing Lou; Xueyan Zhang; Huiming Wang; Baohui Han
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-04       Impact factor: 4.553

10.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.